Relmada Reports Strong NDV-01 Phase 2 Data, Extends Cash Runway to 2029, Advances to Phase 3

summarizeSummary

Relmada Therapeutics reported positive 12-month Phase 2 data for its lead candidate NDV-01, secured a cash runway through 2029, and is on track to initiate Phase 3 trials and file new patents, significantly de-risking its development programs.

check_boxKey Events

• Extended Cash Runway to 2029

  The company reported a cash balance of $234.0 million as of March 31, 2026, which is expected to fund operations through 2029, including the completion of the NDV-01 Phase 3 RESCUE program. This follows a recent $160 million private placement and resolves prior going concern status.

• Positive NDV-01 Phase 2 Data

  12-month Phase 2 data for NDV-01 in high-risk non-muscle invasive bladder cancer (NMIBC) demonstrated a 95% complete response (CR) rate at any time and a durable 76% CR rate at 12 months. In the BCG-unresponsive subpopulation, CR rates were 94% at any time and 80% at 12 months, with favorable tolerability.

• Advancing NDV-01 to Phase 3

  Relmada is on track to file the NDV-01 IND and initiate the Phase 3 RESCUE registrational program in mid-2026, with FDA alignment confirmed for two independent development pathways.

• New Patent Application for NDV-01

  A provisional patent application was filed with the USPTO in April 2026 covering NDV-01 pharmaceutical formulations and methods of treatment, potentially extending patent protection until April 2047 if issued.

auto_awesomeAnalysis

This filing provides detailed positive updates on Relmada's clinical pipeline and financial stability. The strong cash position, extended runway through 2029, and resolution of prior going concern status significantly de-risk the company's operations. The robust 12-month Phase 2 data for NDV-01, coupled with FDA alignment and a clear path to Phase 3, reinforces its potential as a best-in-class therapy for bladder cancer. The new patent application further strengthens the long-term value of NDV-01. These developments are critical for a clinical-stage biotechnology company, indicating significant progress towards commercialization and reducing immediate funding concerns.